Stay updated on Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Sign up to get notified when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.

Latest updates to the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page
- ChecktodayChange DetectedThe ClinicalTrials.gov footer revision indicator updates from v3.8.0 to v3.8.1.SummaryDifference0.1%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedThe ClinicalTrials.gov record for a phase II colorectal cancer study is displayed, including its treatment plan, eligibility criteria, outcomes, recruitment location, and study contacts.SummaryDifference39%

- Check21 days agoChange DetectedThe footer now identifies the ClinicalTrials.gov site as revision v3.8.0 instead of v3.7.2.SummaryDifference0.2%

- Check28 days agoChange DetectedA banner announces an NIH-wide transition and says that “Super Intelligence” may appear in place of “Artificial Intelligence” across NIH content.SummaryDifference1%

- Check35 days agoChange DetectedThe footer’s site revision label changes from v3.7.1 to v3.7.2 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check42 days agoChange DetectedThe ClinicalTrials.gov footer now displays revision v3.7.1 instead of v3.7.0.SummaryDifference0.2%

Stay in the know with updates to Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Fruquintinib Plus Sintilimab in CRC 3rd-line Clinical Trial page.